Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course. The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined. The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes. Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings. Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations. Unsupervised hierarchical clustering analysis revealed a distinct separation between clusters containing borderline and high-grade lesions. The majority of low-grade tumors clustered with LMP tumors. Comparing OSE with high-grade and LMP expression profiles revealed enhanced expression of genes linked to cell proliferation, chromosomal instability, and epigenetic silencing in high-grade cancers, whereas LMP tumors displayed activated p53 signaling. The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers. Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.

[1]  J. Little,et al.  Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status , 1995, The Journal of Biological Chemistry.

[2]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[3]  R. Kurman,et al.  Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. , 1996, The American journal of surgical pathology.

[4]  L. Morrison,et al.  Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. , 2003, Cancer research.

[5]  C. Arrowsmith,et al.  Placental Transforming Growth Factor-β Is a Downstream Mediator of the Growth Arrest and Apoptotic Response of Tumor Cells to DNA Damage and p53 Overexpression* , 2000, The Journal of Biological Chemistry.

[6]  R. Sclafani,et al.  Differential regulation of the yeast CDC7 gene during mitosis and meiosis , 1988, Molecular and cellular biology.

[7]  A. Sabichi,et al.  Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth , 2003, Oncogene.

[8]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[9]  T. Hasan,et al.  Integrin-mediated adhesion and signalling in ovarian cancer cells. , 1998, Cellular signalling.

[10]  C. Marshall,et al.  Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1 , 1998, Nature.

[11]  V. Rotter,et al.  Activated p53 suppresses the histone methyltransferase EZH2 gene , 2004, Oncogene.

[12]  M. Oren,et al.  Cell Cycle Regulation and p53 Activation by Protein Phosphatase 2Cα* , 2003, The Journal of Biological Chemistry.

[13]  A. Jazaeri,et al.  Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  C. Sotiriou,et al.  Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma , 2003, Molecular carcinogenesis.

[15]  S. Asa.  Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. , 1999 .

[16]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[18]  P. Pelicci,et al.  PML interaction with p53 and its role in apoptosis and replicative senescence , 2001, Oncogene.

[19]  R. Scully,et al.  Early de novo ovarian carcinoma. A study of fourteen cases , 1994, Cancer.

[20]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[21]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[22]  G. Atweh,et al.  Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. , 2002, The Mount Sinai journal of medicine, New York.

[23]  R. Berkowitz,et al.  Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. , 2000, The American journal of pathology.

[24]  P. Nurse,et al.  Regulated expression and phosphorylation of a possible mammalian cell-cycle control protein , 1988, Nature.

[25]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[26]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[27]  Anil K Sood,et al.  Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. , 2004, The American journal of pathology.

[28]  E. Ruoslahti,et al.  A novel fibronectin receptor with an unexpected subunit composition (alpha v beta 1). , 1990, The Journal of biological chemistry.

[29]  J. Trimarchi,et al.  E2f3 is critical for normal cellular proliferation. , 2000, Genes & development.

[30]  R. Kurman,et al.  Noninvasive and Invasive Micropapillary (Low-Grade) Serous Carcinoma of the Ovary: A Clinicopathologic Analysis of 135 Cases , 2003, The American journal of surgical pathology.

[31]  Y. Ishino,et al.  The clamp-loading complex for processive DNA replication , 2004, Nature Structural &Molecular Biology.

[32]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[33]  M. Birrer,et al.  p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. , 1993, Cancer research.

[34]  Mingyao Liu,et al.  GCIP, a Novel Human Grap2 and Cyclin D Interacting Protein, Regulates E2F-mediated Transcriptional Activity* , 2000, The Journal of Biological Chemistry.

[35]  E. Seroussi,et al.  Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein* , 2001, The Journal of Biological Chemistry.

[36]  N. Sonenberg,et al.  The Transformation Suppressor Pdcd4 Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits Translation , 2003, Molecular and Cellular Biology.

[37]  H. Saya,et al.  CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. , 2003, Developmental cell.

[38]  S. Love,et al.  Proliferating cell nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer? , 1995, British Journal of Cancer.

[39]  Susan L. Forsburg,et al.  Eukaryotic MCM Proteins: Beyond Replication Initiation , 2004, Microbiology and Molecular Biology Reviews.

[40]  R. Fehon,et al.  Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity , 2003, Nature.

[41]  P. Meltzer,et al.  Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  F. Townsley,et al.  Cdc20 associates with the kinase aurora2/Aik. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Bodurka,et al.  Response and Survival in Patients With Progressive or Recurrent Serous Ovarian Tumors of Low Malignant Potential , 2002, Obstetrics and gynecology.

[44]  C. Staedel,et al.  Altered adhesion properties and alpha v integrin expression in a cisplatin‐resistant human ovarian carcinoma cell line , 2002, International journal of cancer.

[45]  P. Clement,et al.  Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament: Atlas of Tumor Pathology , 1999 .

[46]  S. Nasim,et al.  Evaluation of a linear amplification method for small samples used on high-density oligonucleotide microarray analysis. , 2004, Analytical biochemistry.

[47]  K. Guan,et al.  PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway , 2000 .

[48]  A. Levine,et al.  Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction , 1999, Oncogene.

[49]  Robert E. Johnson,et al.  Efficient and accurate replication in the presence of 7,8-dihydro-8-oxoguanine by DNA polymerase η , 2000, Nature Genetics.

[50]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[51]  Joanna H Shih,et al.  Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways , 2004, Oncogene.

[52]  R. Kurman,et al.  Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. , 1999, The American journal of surgical pathology.